Top-Rated StocksTop-RatedNASDAQ:EXAS Exact Sciences (EXAS) Stock Price, News & Analysis → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free EXAS Stock Alerts $53.02 -1.13 (-2.09%) (As of 10:16 AM ET) Add Compare Share Share Today's Range$52.95▼$55.4050-Day Range$54.15▼$74.2652-Week Range$52.25▼$100.77Volume909,566 shsAverage Volume2.36 million shsMarket Capitalization$9.75 billionP/E RatioN/ADividend YieldN/APrice Target$95.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Exact Sciences alerts: Email Address Exact Sciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.92 Rating ScoreUpside/Downside76.2% Upside$95.40 Price TargetShort InterestBearish5.38% of Shares Sold ShortDividend StrengthN/ASustainability-0.83Upright™ Environmental ScoreNews Sentiment0.32Based on 27 Articles This WeekInsider TradingSelling Shares$4.26 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.86) to $0.02 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.00 out of 5 starsMedical Sector207th out of 915 stocksMedical Laboratories Industry8th out of 19 stocks 3.5 Analyst's Opinion Consensus RatingExact Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 12 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageExact Sciences has only been the subject of 4 research reports in the past 90 days.Read more about Exact Sciences' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.38% of the outstanding shares of Exact Sciences have been sold short.Short Interest Ratio / Days to CoverExact Sciences has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Exact Sciences has recently increased by 55.99%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldExact Sciences does not currently pay a dividend.Dividend GrowthExact Sciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreExact Sciences has received a 74.50% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private genetic testing services", "Biochemical assay kits for colorectal cancer diagnostics", and "Biochemical assay kits for liver cancer diagnostics" products. See details.Environmental SustainabilityThe Environmental Impact score for Exact Sciences is -0.83. Previous Next 2.4 News and Social Media Coverage News SentimentExact Sciences has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 27 news articles for Exact Sciences this week, compared to 8 articles on an average week.Search Interest25 people have searched for EXAS on MarketBeat in the last 30 days. This is an increase of 19% compared to the previous 30 days.MarketBeat FollowsOnly 12 people have added Exact Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exact Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,255,377.00 in company stock.Percentage Held by InsidersOnly 1.30% of the stock of Exact Sciences is held by insiders.Percentage Held by Institutions88.82% of the stock of Exact Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Exact Sciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Exact Sciences are expected to grow in the coming year, from ($0.86) to $0.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exact Sciences is -47.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exact Sciences is -47.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExact Sciences has a P/B Ratio of 3.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Exact Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Exact Sciences Stock (NASDAQ:EXAS)Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Read More EXAS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EXAS Stock News HeadlinesMay 3, 2024 | insidertrades.comExact Sciences Co. (NASDAQ:EXAS) CEO Kevin T. Conroy Sells 1,155 SharesMay 10, 2024 | markets.businessinsider.comOptimistic Outlook for Exact Sciences: Overcoming Challenges with Growth Initiatives and New Product PotentialMay 10, 2024 | OIC (Ad)[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueJoin us for an exploration of essential volatility concepts in our "Volatility Fundamentals II: Skew & Relative Value" session. OIC® instructor Ken Keating will guide you through important topics that options investors should understand. May 10, 2024 | finance.yahoo.comExact Sciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 10, 2024 | businesswire.comThe National Institute for Health and Care Excellence (NICE) Recommends Use of Exact Sciences' Oncotype DX® Test to Help Guide Chemotherapy Decisions for Node-positive Breast Cancer PatientsMay 9, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Exact Sciences (EXAS)May 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Exact Sciences on Strong Performance and Promising Growth InitiativesMay 9, 2024 | markets.businessinsider.comBuy Rating Reiterated for Exact Sciences on Strong Q1 Performance and Positive Financial OutlookMay 10, 2024 | OIC (Ad)[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueJoin us for an exploration of essential volatility concepts in our "Volatility Fundamentals II: Skew & Relative Value" session. OIC® instructor Ken Keating will guide you through important topics that options investors should understand. May 9, 2024 | finance.yahoo.comQ1 2024 Exact Sciences Corp Earnings CallMay 9, 2024 | finance.yahoo.comExact Sciences Corporation (NASDAQ:EXAS) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.comExact Sciences Stock, A Cathie Wood Darling, Tumbles On 'Overblown' Growth ConcernsMay 9, 2024 | benzinga.comExact Sciences Reports Q1 Loss, Joins Beyond Meat, Duolingo And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionMay 9, 2024 | finance.yahoo.comExact Sciences Corp (EXAS) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth ...May 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Exact Sciences Amidst Strong Growth and Innovative PipelineMay 9, 2024 | msn.comExact Sciences (EXAS) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comExact Sciences Announces First-Quarter 2024 ResultsMay 8, 2024 | msn.comExact Sciences GAAP EPS of -$0.60 misses by $0.11, revenue of $637.52M beats by $10.71MMay 8, 2024 | msn.comExact Sciences Stock Plunges On Q1 Earnings: What You Need To KnowMay 7, 2024 | finance.yahoo.comExact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW® 2024May 4, 2024 | americanbankingnews.comKevin T. Conroy Sells 1,155 Shares of Exact Sciences Co. (NASDAQ:EXAS) StockMay 3, 2024 | americanbankingnews.comExact Sciences Co. (NASDAQ:EXAS) Given Average Rating of "Moderate Buy" by AnalystsMay 1, 2024 | businesswire.comExact Sciences to Participate in May Investor ConferenceMay 1, 2024 | americanbankingnews.comExact Sciences (EXAS) to Release Quarterly Earnings on WednesdayApril 24, 2024 | finance.yahoo.comHere’s Why Baron Health Care Fund Reduced Exact Sciences Corporation (EXAS)April 17, 2024 | finance.yahoo.comExact Sciences Corporation's (NASDAQ:EXAS) Profit OutlookApril 15, 2024 | markets.businessinsider.comExact Sciences Appoints Aaron Bloomer As Chief Financial OfficerSee More Headlines Receive EXAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2024Today5/10/2024Next Earnings (Estimated)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryBiotechnology Current SymbolNASDAQ:EXAS CUSIP30063P10 CIK1124140 Webwww.exactsciences.com Phone(608) 284-5700Fax608-284-5701Employees6,600Year Founded1995Price Target and Rating Average Stock Price Target$95.40 High Stock Price Target$121.00 Low Stock Price Target$80.00 Potential Upside/Downside+76.2%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($1.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-204,150,000.00 Net Margins-8.17% Pretax Margin-8.07% Return on Equity-6.60% Return on Assets-3.20% Debt Debt-to-Equity Ratio0.74 Current Ratio2.32 Quick Ratio2.07 Sales & Book Value Annual Sales$2.50 billion Price / Sales3.98 Cash Flow$0.01 per share Price / Cash Flow3,644.59 Book Value$17.39 per share Price / Book3.11Miscellaneous Outstanding Shares183,850,000Free Float181,460,000Market Cap$9.96 billion OptionableOptionable Beta1.26 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Kevin T. Conroy (Age 58)Chairman of The Board & CEO Comp: $1.54MMr. Jeffrey T. Elliott CFA (Age 46)EVP & CFO Comp: $518.13kMs. Sarah Condella (Age 43)Executive Vice President of Human Resources Comp: $742.76kMr. Everett V. Cunningham (Age 58)Chief Commercial Officer Comp: $1.34MDr. Jorge A. Garces Ph.D. (Age 52)Chief Science Officer Mr. Nassar NizamiChief Information OfficerMs. Megan JonesAssociate Manager of Investor RelationsMr. Tim CaprezChief Compliance Counsel & VPMr. James Herriott (Age 44)Senior VP, General Counsel & Secretary Mr. Vic ParkerHead of SalesMore ExecutivesKey CompetitorsNateraNASDAQ:NTRAPRA Health SciencesNASDAQ:PRAHQuest DiagnosticsNYSE:DGXExelixisNASDAQ:EXELPPDNASDAQ:PPDView All CompetitorsInsiders & InstitutionsTwin Tree Management LPBought 41,700 shares on 5/10/2024Ownership: 0.000%State Board of Administration of Florida Retirement SystemSold 5,903 shares on 5/9/2024Ownership: 0.103%Mitsubishi UFJ Asset Management Co. Ltd.Bought 12,349 shares on 5/9/2024Ownership: 0.049%Beacon Investment Advisory Services Inc.Sold 7,310 shares on 5/9/2024Ownership: 0.030%Midwest Professional Planners LTD.Bought 339 shares on 5/9/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions EXAS Stock Analysis - Frequently Asked Questions Should I buy or sell Exact Sciences stock right now? 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There are currently 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EXAS shares. View EXAS analyst ratings or view top-rated stocks. What is Exact Sciences' stock price target for 2024? 13 Wall Street research analysts have issued 1 year price targets for Exact Sciences' shares. Their EXAS share price targets range from $80.00 to $121.00. On average, they expect the company's stock price to reach $95.40 in the next twelve months. This suggests a possible upside of 76.2% from the stock's current price. View analysts price targets for EXAS or view top-rated stocks among Wall Street analysts. How have EXAS shares performed in 2024? Exact Sciences' stock was trading at $73.98 at the beginning of 2024. Since then, EXAS shares have decreased by 26.8% and is now trading at $54.15. View the best growth stocks for 2024 here. Are investors shorting Exact Sciences? Exact Sciences saw a increase in short interest in April. As of April 15th, there was short interest totaling 9,890,000 shares, an increase of 56.0% from the March 31st total of 6,340,000 shares. Based on an average trading volume of 2,390,000 shares, the days-to-cover ratio is presently 4.1 days. View Exact Sciences' Short Interest. When is Exact Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024. View our EXAS earnings forecast. How were Exact Sciences' earnings last quarter? Exact Sciences Co. (NASDAQ:EXAS) posted its quarterly earnings results on Wednesday, February, 21st. The medical research company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.26. The medical research company had revenue of $646.89 million for the quarter, compared to analyst estimates of $638.83 million. Exact Sciences had a negative trailing twelve-month return on equity of 6.60% and a negative net margin of 8.17%. The firm's revenue was up 17.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.72) EPS. What ETFs hold Exact Sciences' stock? ETFs with the largest weight of Exact Sciences (NASDAQ:EXAS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Tema Oncology ETF (CANC), First Trust NYSE Arca Biotechnology Index Fund (FBT), Fidelity Disruptive Medicine ETF (FMED), Principal Healthcare Innovators ETF (BTEC), Putnam BioRevolution ETF (SYNB) and VanEck Biotech ETF (BBH). What guidance has Exact Sciences issued on next quarter's earnings? Exact Sciences updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.8 billion. What is Kevin T. Conroy's approval rating as Exact Sciences' CEO? 328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 69.0% of employees surveyed would recommend working at Exact Sciences to a friend. What other stocks do shareholders of Exact Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL), Block (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV). Who are Exact Sciences' major shareholders? Exact Sciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (1.09%), Baillie Gifford & Co. (0.93%), Nikko Asset Management Americas Inc. (0.83%), Zevenbergen Capital Investments LLC (0.74%), Principal Financial Group Inc. (0.60%) and Peregrine Capital Management LLC (0.36%). Insiders that own company stock include Brian Baranick, Canada Pension Plan Investment, D Scott Coward, Daniel J Levangie, Everett Cunningham, Jacob A Orville, James Edward Doyle, James Herriott, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy and Sarah Condella. View institutional ownership trends. How do I buy shares of Exact Sciences? Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Exact Sciences have any subsidiaries? The following companies are subsidiares of Exact Sciences: Armune BioScience, Ashion Analytics, Base Genomics Limited, Biomatrica Inc., Exact Sciences Development Company LLC, Exact Sciences Laboratories LLC, Genomic Health Inc., Genomic Health International Holdings LLC, Paradigm Diagnostics Inc., Sampleminded Inc., Thrive Earlier Detection Corporation, and Viomics Inc..Read More This page (NASDAQ:EXAS) was last updated on 5/10/2024 by MarketBeat.com Staff From Our Partners[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICThis 1 Biotech Stock has been shocking the marketsHuge AlertsHe Is Giving Away BitcoinCrypto Swap ProfitsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityYou need to know these two things about AI stocks ASAP…InvestorPlaceTrump Asset Seizure Threat Alert: Could Your Savings Be Next?American Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.